Effect of a synthetic inhibitor of urokinase plasminogen activator on the migration and invasion of human cervical cancer cells in vitro

Wang,Xuechun; Jiang,Zhongqing; An,Jian; Mao,Xiaodan; Lin,Fen; Sun,Pengming

doi:10.3892/mmr.2018.8414

Effect of a synthetic inhibitor of urokinase plasminogen activator on the migration and invasion of human cervical cancer cells in vitro

Authors:
- Xuechun Wang
- Zhongqing Jiang
- Jian An
- Xiaodan Mao
- Fen Lin
- Pengming Sun
View Affiliations

Affiliations: Laboratory of Gynecologic Oncology, Fujian Provincial Maternity and Children Hospital, Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China, Department of Gynecology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian 361009, P.R. China
Published online on: January 9, 2018 https://doi.org/10.3892/mmr.2018.8414
Pages: 4273-4280
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As a notable feature of malignant tumors, invasion and metastasis are important events in the process of tumor progression. Amiloride, a synthetic inhibitor of urokinase plasminogen activator (uPA), is involved in these events. To evaluate the therapeutic value of amiloride in cervical cancer, HeLa cells were used as in vitro cellular models. The migration and invasion abilities of HeLa cells, in addition to the mRNA expression of matriptase, uPA, uPA receptor and 72 kDa type IV collagenase (MMP‑2), were detected using scratch assays, Transwell chamber assays and reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR). The results of RT‑qPCR demonstrated that the mRNA expression of uPA and MMP‑2 in HeLa cells was downregulated significantly in a dose‑dependent manner when incubated with various concentrations of amiloride for 24 h. The migration distance of HeLa cells was significantly shorter at 6, 12 and 24 h following incubation with amiloride (P<0.01), and there was a positive correlation between cell migratory ability and cellular uPA protein expression level (r=0.955, P<0.01). The number of HeLa cells that penetrated the Matrigel following incubation for 24 h with different concentrations of amiloride decreased significantly compared with the control group, indicating that cell invasiveness was positively correlated with the protein expression level of uPA in the cells (r=0.993, P<0.01). The present study demonstrated that amiloride was able to specifically inhibit the mRNA expression levels of uPA in HeLa cells, and sequentially downregulate the mRNA expression of downstream MMP‑2 in the uPA system, thereby suppressing the migratory and invasive ability of HeLa cells. Therefore, amiloride may be a promising therapeutic target for the treatment of cervical cancer.

View Figures

View References

1	de Sanjosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N and Bosch FX: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet Infect Dis. 7:453–459. 2007. View Article : Google Scholar : PubMed/NCBI
2	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN, 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
3	Sahasrabuddhe VV, Parham GP, Mwanahamuntu MH and Vermund SH: Cervical cancer prevention in low- and middle-income countries: Feasible, affordable, essential. Cancer Prev Res (Phila). 5:11–17. 2011. View Article : Google Scholar : PubMed/NCBI
4	Hildenbrand R, Allgayer H, Marx A and Stroebel P: Modulators of the urokinase-type plasminogen activation system for cancer. Expert Opin Invest Drugs. 19:641–652. 2010. View Article : Google Scholar
5	Blasi F and Sidenius N: The urokinase receptor: Focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett. 584:1923–1930. 2010. View Article : Google Scholar : PubMed/NCBI
6	Mekkawy AH, Morris DL and Pourgholami MH: Urokinase plasminogen activator system as a potential target for cancer therapy. Future Oncol. 5:1487–1499. 2009. View Article : Google Scholar : PubMed/NCBI
7	Daneri-Navarro A, Macias-Lopez G, Oceguera-Villanueva A, Del Toro-Arreola S, Bravo-cuellar A, Perez-montfort R and Orbach-arbouys S: Urokinase-type plasminogen activator and plasminogen activator inhibitors (PAI-1 and PAI-2) in extracts of invasive cervical carcinoma and precursor lesions. Eur J Cancer. 34:566–569. 1998. View Article : Google Scholar : PubMed/NCBI
8	Santin AD, Cane' S, Bellone S, Bignotti E, Palmieri M, De Las Casas LE, Anfossi S, Roman JJ, O'Brien T and Pecorelli S: The novel serine protease tumor-associated differentially expressed gene-15 (matriptase/MT-SP1) is highly overexpressed in cervical carcinoma. Cancer. 98:1898–1904. 2003. View Article : Google Scholar : PubMed/NCBI
9	Watanabe H: Extracellular matrix-regulation of cancer invasion and metastasis. Gan To Kagaku Ryoho. 37:2058–2061. 2010.PubMed/NCBI
10	Webb SL, Sanders AJ, Mason MD and Jiang WG: Type II transmembrane serine protease (TTSP) deregulation in cancer. Front Biosci. 16:539–552. 2011. View Article : Google Scholar
11	Zitka O, Kukacka J, Krizkova S, Huska D, Adam V, Masarik M, Prusa R and Kizek R: Matrix metalloproteinases. Curr Med Chem. 17:3751–3768. 2010. View Article : Google Scholar : PubMed/NCBI
12	List K: Matriptase: A culprit in cancer? Future Oncol. 5:97–104. 2009. View Article : Google Scholar : PubMed/NCBI
13	Jankun J and Skrzypczakjankun E: Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride. Cancer Biochem Biophys. 17:109–123. 1999.PubMed/NCBI
14	Vassalli JD and Belin D: Amiloride selectively inhibits the urokinase-type plasminogen activator. FEBS Lett. 214:187–191. 1987. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Liu Y, Han Y, Zhang H, Nie L, Jiang Z, Fa P, Gui Y and Cai Z: Synthetic miRNA-Mowers targeting miR-183-96-182 cluster or miR-210 inhibit growth and migration and induce apoptosis in bladder cancer cells. PLoS One. 7:e522802012. View Article : Google Scholar : PubMed/NCBI
17	Qi S, Song Y, Peng Y, Wang H, Long H, Yu X, Li Z, Fang L, Wu A, Luo W, et al: ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion and apoptosis in glioma. PLoS One. 7:e388422012. View Article : Google Scholar : PubMed/NCBI
18	Mignatti P and Rifkin DB: Biology and biochemistry of proteinases in tumor invasion. Physiol Rev. 73:161–195. 1993. View Article : Google Scholar : PubMed/NCBI
19	Jones JL and Walker RA: Control of matrix metalloproteinase activity in cancer. J Pathol. 183:377–399. 1997. View Article : Google Scholar : PubMed/NCBI
20	Lijnen HR: Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry. 67:92–98. 2002.PubMed/NCBI
21	Overall CM and Kleifeld O: Tumour microenvironment-opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nature Rev Cancer. 6:227–239. 2006. View Article : Google Scholar
22	Libra M, Scalisi A, Vella N, Clementi S, Sorio R, Stivala F, Spandidos DA and Mazzarino C: Uterine cervical carcinoma: Role of matrix metalloproteinases (Review). Int J Oncol. 34:897–903. 2009. View Article : Google Scholar : PubMed/NCBI
23	Baltazarrodriguez LM, Anayaventura A, Andradesoto M, Monrroy-Guizar EA, Bautista-Lam JR, Jonguitud-Olguin G, Cepeda-Lopez FR, Centeno-Aguilar VA, Gonzalez-Hernandez NA, Soriano-Hernández AD, et al: Polymorphism in the matrix metalloproteinase-2 gene promoter is associated with cervical neoplasm risk in Mexican women. Biochem Genet. 46:137–144. 2008. View Article : Google Scholar : PubMed/NCBI
24	Lin CY, Tseng IC, Chou FP, Su SF, Chen YW, Johnson MD and Dickson RB: Zymogen activation, inhibition and ectodomain shedding of matriptase. Front Biosci. 13:621–635. 2008. View Article : Google Scholar : PubMed/NCBI
25	Lee JW, Song S, Choi JJ, Lee SJ, Kim BG, Park CS, Lee JH, Lin CY, Dickson RB and Bae DS: Increased expression of matriptase is associated with histopathologic grades of cervical neoplasia. Hum Pathol. 36:626–633. 2005. View Article : Google Scholar : PubMed/NCBI
26	Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS and Skriver L: Plasminogen activators, tissue degradation and cancer. Adv Cancer Res. 44:139–266. 1985. View Article : Google Scholar : PubMed/NCBI
27	Saksela O and Rifkin DB: Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol. 4:93–126. 1988. View Article : Google Scholar : PubMed/NCBI
28	Wang Y, Jones CJ and Dang J: Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells. FEBS Lett. 353:138–142. 1994. View Article : Google Scholar : PubMed/NCBI
29	Wang Y, Dang J, Liang X and Doe WF: Amiloride modulates urokinase gene expression at both transcription and post-transcription levels in human colon cancer cells. Clin Exp Metastasis. 13:196–202. 1995. View Article : Google Scholar : PubMed/NCBI
30	Klinghofer V, Stewart K, Mcgonigal T, Smith R, Sarthy A, Nienaber V, Butler C, Dorwin S, Richardson P, Weitzberg M, et al: Species specificity of amidine-based urokinase inhibitors. Biochemistry. 40:9125–9131. 2001. View Article : Google Scholar : PubMed/NCBI
31	Park KS, Poburko D, Wollheim CB and Demaurex N: Amiloride derivatives induce apoptosis by depleting ER Ca(2+) stores in vascular endothelial cells. Br J Pharmacol. 156:1296–1304. 2009. View Article : Google Scholar : PubMed/NCBI
32	Matthews H, Ranson M and Kelso MJ: Anti-tumour/metastasis effects of the potassium-sparing diuretic amiloride: An orally active anti-cancer drug waiting for its call-of-duty? Int J Cancer. 129:2051–2061. 2011. View Article : Google Scholar : PubMed/NCBI